| Bioactivity | Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells[1]. | ||||||||||||
| Invitro | Barasertib-HQPA (3 μM, 3 hours) significantly decreases expression of the phosphorylated forms of histone H3 in freshly isolated leukemia cells[1].Barasertib-hydroxyquinazoline pyrazol anilide (HQPA)] is converted rapidly to the active Barasertib-HQPA in plasma[2].Barasertib-HQPA is used for the in vitro experiments[3].Barasertib-HQPA induces a marked anti-propliferative effect accompanied by the appearance of a polyploid population, which in most cases led to apoptosis[4]. | ||||||||||||
| Name | Barasertib | ||||||||||||
| CAS | 722543-31-9 | ||||||||||||
| Formula | C26H31FN7O6P | ||||||||||||
| Molar Mass | 587.54 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Barasertib
CAS: 722543-31-9 F: C26H31FN7O6P W: 587.54
Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.